trending Market Intelligence /marketintelligence/en/news-insights/trending/_atcybbhbpmc_ow-8ozkfw2 content esgSubNav
In This List

InVivo gets another Nasdaq noncompliance notice

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


InVivo gets another Nasdaq noncompliance notice

InVivo Therapeutics Holdings Corp. said it was no longer in compliance with another Nasdaq listing requirement, this one requiring that the company maintain a minimum stockholders' equity of $10.0 million.

According to the Nasdaq's Listing Qualifications Department, InVivo's stockholders' equity was about $8.3 million for the quarter ended March 31.

InVivo has until June 25 to provide a plan to regain compliance. If approved, the company has 180 calendar days, or until Nov. 7, to regain compliance with all Nasdaq Global Market listing requirements.

The company had previously received a deficiency letter for failing to meet Nasdaq's minimum bid price requirement.

Cambridge, Mass.-based InVivo is a biomaterials and biotechnology company.